More on TVRD

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+5.1% Growth)
- Ratings (7.8 Score)

Upcoming Events

- Earnings (11/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Tvardi Therapeutics (NQ:TVRD)
Delayed: 1.84 -0.01 (0.54%)
Prev. Close $1.85  
Open$1.83 
52 Wk High$ 
52 Wk Low$ 
Day High$1.90 
Day Low$1.81 
P/E N/A  
EPS$ 
Volume77,504 


Sep 8, 2026 06:36 AM Lucid Capital Markets Starts Tvardi Therapeutics Inc (TVRD) at Buy
Aug 26, 2026 08:00 AM Tvardi Therapeutics to Participate in Upcoming Investor Events
Aug 17, 2026 06:50 AM H.C. Wainwright Reiterates Buy Rating on Tvardi Therapeutics Inc (TVRD)
Aug 14, 2026 07:31 AM Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
Aug 14, 2026 07:11 AM Form 10-Q Tvardi Therapeutics, For: Jun 30
Aug 14, 2026 07:05 AM Form 8-K Tvardi Therapeutics, For: Aug 14
Aug 14, 2026 07:00 AM Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Aug 12, 2026 08:00 AM Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
Jul 30, 2026 07:31 AM Form 8-K Tvardi Therapeutics, For: Jul 30
Jul 30, 2026 07:30 AM Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
View All Articles

Entities mentioned with TVRD

View All Entities